广东省联盟中成药集采政策实施与成效研究  

Study on the Implementation and Effect of Guangdong Chinese Patent Medicine Centralized Purchase Alliance

作　　者：杜润泽 麦懿漾 谭清立 DU Run-ze;MAI Yi-yang;TAN Qing-li(School of Medical Business,Guangdong Pharmaceutical University,Zhongshan 528400,China;不详)

机构地区：[1]广东药科大学医药商学院,广东中山528400

出　　处：《中国卫生经济》2023年第3期6-9,共4页Chinese Health Economics

基　　金：广东省软科学基金面上项目(2019A101002068)。

摘　　要：加速推进中成药集中带量采购政策,有助于中成药价格体系走向健全化和制度化,同时也为中成药企业的转型提供了机遇,有利于中成药研发与生产的长远发展。广东省作为中成药生产的大省,在集中带量采购工作中,涉及药品品种多达53个,发展势头迅猛。整理与汇总广东省中成药集中带量采购特点,总结其所获成果,对中成药企业的战略调整与未来发展有着指导性作用。The acceleration of the policy of collection of proprietary Chinese medicine prompts the price system of proprietary Chinese medicine to become sound and institutionalized,but also provides opportunities for the transformation of proprietary Chinese medicine enterprises and contributes to the long-term development and production of proprietary Chinese medicine.As a major province of Chinese patent medicine production,Guangdong Province has carried out the collection work,involving as many as 53 varieties,with a rapid development momentum.Based on the characteristics of Chinese patent medicine collection in Guangdong Province,this paper sorted and summarized the data,and summarized the achievements of Chinese patent medicine collection,which has a guiding role for the strategic adjustment and future development of Chinese patent medicine enterprises.

关 键 词：中成药集中带量采购 集中带量采购 医药采购 中成药市场 广东 

分 类 号：R1-9[医药卫生—公共卫生与预防医学] R190